Paper39831789
The fluoroquinolone compounds potentiate the antifungal activity of the echinocandins against Aspergillus fumigatus.
Choi JJ and 8 others. Biosci Rep, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. The fluoroquinolone compounds potentiate the antifungal activity of the echinocandins against Aspergillus fumigatus. Papers, record 39831789. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39831789
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The fluoroquinolone compounds potentiate the antifungal activity of the echinocandins against Aspergillus fumigatus.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Aspergillus fumigatus | Major topic |
| Antifungal Agents | Major topic |
| Fluoroquinolones | Major topic |
| Echinocandins | Major topic |
| Aspergillosis | Major topic |
| Animals | |
| Drug Synergism | |
| Mice | |
| Caspofungin | |
| Drug Resistance, Fungal | |
| Microbial Sensitivity Tests | |
| Humans | |
| Ergosterol | |
| Molecular Docking Simulation | |
| Fungal Proteins |
Source PubMed
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 3111257 | Norfloxacin, a fluoroquinolone antibacterial agent. Classification, mechanism of action, and in vitro activity. | Am J Med | 1987 | https://conductscience.org/library/papers/3111257 | PubMed |
| 2 | 7516863 | Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. | Drugs | 1994 | https://conductscience.org/library/papers/7516863 | PubMed |
| 3 | 28702763 | Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. | Infection | 2017 | https://conductscience.org/library/papers/28702763 | PubMed |
| 4 | 21486730 | Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature. | Eur J Med Res | 2011 | https://conductscience.org/library/papers/21486730 | PubMed |
| 5 | 27927037 | Clinical hepatotoxicity associated with antifungal agents. | Expert Opin Drug Saf | 2017 | https://conductscience.org/library/papers/27927037 | PubMed |
| 6 | 15375111 | Combinations of antifungal agents in therapy--what value are they? | J Antimicrob Chemother | 2004 | https://conductscience.org/library/papers/15375111 | PubMed |
| 7 | 10508721 | Mechanism of fluoroquinolone action. | Curr Opin Microbiol | 1999 | https://conductscience.org/library/papers/10508721 | PubMed |
| 8 | 27379235 | Recognition of Membrane Sterols by Polyene Antifungals Amphotericin B and Natamycin, A (13)C MAS NMR Study. | Front Cell Dev Biol | 2016 | https://conductscience.org/library/papers/27379235 | PubMed |
| 9 | 29773744 | Worldwide emergence of resistance to antifungal drugs challenges human health and food security. | Science | 2018 | https://conductscience.org/library/papers/29773744 | PubMed |
| 10 | 28258218 | Structural analyses of Candida albicans sterol 14α-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis. | J Biol Chem | 2017 | https://conductscience.org/library/papers/28258218 | PubMed |
| 11 | 31021468 | Quinolone derivatives and their antifungal activities: An overview. | Arch Pharm (Weinheim) | 2019 | https://conductscience.org/library/papers/31021468 | PubMed |
| 12 | 26684607 | Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. | Lancet | 2016 | https://conductscience.org/library/papers/26684607 | PubMed |
| 13 | 23550668 | Combination antifungal therapy for cryptococcal meningitis. | N Engl J Med | 2013 | https://conductscience.org/library/papers/23550668 | PubMed |
| 14 | 17569573 | Resistance to echinocandin-class antifungal drugs. | Drug Resist Updat | 2007 | https://conductscience.org/library/papers/17569573 | PubMed |
| 15 | 24715154 | Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy? | Eur J Clin Microbiol Infect Dis | 2014 | https://conductscience.org/library/papers/24715154 | PubMed |
| 16 | 3292209 | Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. | Drugs | 1988 | https://conductscience.org/library/papers/3292209 | PubMed |
| 17 | 26908577 | The Aspergillus fumigatus Damage Resistance Protein Family Coordinately Regulates Ergosterol Biosynthesis and Azole Susceptibility. | mBio | 2016 | https://conductscience.org/library/papers/26908577 | PubMed |
| 18 | 15578352 | Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. | Clin Infect Dis | 2004 | https://conductscience.org/library/papers/15578352 | PubMed |
| 19 | 27381395 | Aspergillus fumigatus Intrinsic Fluconazole Resistance Is Due to the Naturally Occurring T301I Substitution in Cyp51Ap. | Antimicrob Agents Chemother | 2016 | https://conductscience.org/library/papers/27381395 | PubMed |
| 20 | 16989123 | [Emerging azole antifungals]. | Therapie | 2006 | https://conductscience.org/library/papers/16989123 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39831789
GET https://conductscience.org/api/papers/v1/39831789/references?page=2